ImpediMed Limited (ASX:IPD)

Market Cap	18.31M -79.5%
Revenue (ttm)	14.61M +14.8%
Net Income	-24.91M
EPS	-0.01
Shares Out	3.66B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,161,597
Open	0.0050
Previous Close	0.0050
Day's Range	0.0050 - 0.0050
52-Week Range	0.0030 - 0.0550
Beta	1.06
Analysts	Strong Buy
Price Target	0.02 (+300.0%)
Earnings Date	Oct 27, 2026

About ImpediMed

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fl...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 77
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IPD

Financial Performance

In fiscal year 2026, ImpediMed's revenue was 14.61 million, an increase of 14.85% compared to the previous year's 12.72 million. Losses were -24.91 million, 7.19% more than in 2025.

Analyst Summary

According to 4 analysts, the average rating for IPD stock is "Strong Buy." The 12-month stock price target is $0.02, which is an increase of 300.00% from the latest price.

Price Target

$0.02

(300.00% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 28, 2026

Data Sources Report a data error